Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $41.8333.

Several equities analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright raised their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Canaccord Genuity Group lifted their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Wedbush upped their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Finally, Loop Capital set a $35.00 target price on shares of Stoke Therapeutics in a research note on Monday, January 5th.

Insider Buying and Selling

In other news, insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total value of $174,200.00. Following the completion of the sale, the insider directly owned 31,339 shares in the company, valued at $1,253,560. The trade was a 12.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Adrian R. Krainer sold 33,243 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $39.74, for a total value of $1,321,076.82. Following the transaction, the director directly owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. The trade was a 10.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 69,699 shares of company stock worth $2,526,714 in the last ninety days. 9.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP increased its holdings in Stoke Therapeutics by 8.3% in the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after acquiring an additional 423,331 shares in the last quarter. Morgan Stanley lifted its holdings in Stoke Therapeutics by 0.3% during the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after purchasing an additional 9,108 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after purchasing an additional 217,616 shares during the period. State Street Corp grew its position in shares of Stoke Therapeutics by 75.2% in the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock valued at $79,288,000 after purchasing an additional 1,072,176 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of Stoke Therapeutics by 7.9% during the second quarter. Marshall Wace LLP now owns 2,300,554 shares of the company’s stock worth $26,111,000 after purchasing an additional 168,771 shares in the last quarter.

Stoke Therapeutics Stock Up 2.5%

Stoke Therapeutics stock opened at $32.56 on Wednesday. The business’s 50-day moving average price is $33.09 and its 200 day moving average price is $30.70. The firm has a market cap of $1.93 billion, a price-to-earnings ratio of -271.31 and a beta of 1.07. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.97) earnings per share (EPS) for the quarter. Stoke Therapeutics had a negative net margin of 3.73% and a negative return on equity of 2.05%. The company had revenue of $1.40 million during the quarter. Equities analysts expect that Stoke Therapeutics will post -2.01 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.